MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Zai Lab Ltd ADR

Geschlossen

BrancheGesundheitswesen

29.4 -5.41

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

28.85

Max

31.06

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.7M

-41M

Verkäufe

3.5M

110M

Gewinnspanne

-37.032

Angestellte

1,869

EBITDA

1.4M

-55M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+68.33% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-700M

3.5B

Vorheriger Eröffnungskurs

34.81

Vorheriger Schlusskurs

29.4

Nachrichtenstimmung

By Acuity

100%

0%

357 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Okt. 2025, 22:33 UTC

Ergebnisse

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14. Okt. 2025, 22:21 UTC

Wichtige Markttreiber

Dentsply Sirona Shares Rise After SEC Probe Ends

14. Okt. 2025, 19:27 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14. Okt. 2025, 17:56 UTC

Wichtige Markttreiber

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14. Okt. 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14. Okt. 2025, 22:12 UTC

Market Talk
Ergebnisse

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14. Okt. 2025, 21:40 UTC

Ergebnisse

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14. Okt. 2025, 21:39 UTC

Ergebnisse

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14. Okt. 2025, 21:38 UTC

Ergebnisse

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14. Okt. 2025, 21:06 UTC

Ergebnisse

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

14. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. Okt. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Health Care Roundup: Market Talk

14. Okt. 2025, 20:13 UTC

Ergebnisse

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14. Okt. 2025, 20:01 UTC

Ergebnisse

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14. Okt. 2025, 19:21 UTC

Market Talk
Ergebnisse

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14. Okt. 2025, 19:12 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14. Okt. 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14. Okt. 2025, 18:59 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14. Okt. 2025, 18:58 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14. Okt. 2025, 18:58 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14. Okt. 2025, 18:56 UTC

Akquisitionen, Fusionen, Übernahmen

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14. Okt. 2025, 18:46 UTC

Ergebnisse

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14. Okt. 2025, 18:04 UTC

Ergebnisse

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14. Okt. 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14. Okt. 2025, 17:54 UTC

Ergebnisse

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14. Okt. 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Okt. 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

68.33% Vorteil

12-Monats-Prognose

Durchschnitt 52.57 USD  68.33%

Hoch 69 USD

Tief 39 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

6

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

28.13 / 31.12Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat